Switching chemo Mid-Treatment shows promise for tough pancreatic cancers
NCT ID NCT04539808
First seen Nov 15, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study tests whether switching from one chemotherapy combination to another before surgery can help people with pancreatic cancer that can be removed or has spread nearby. About 42 adults with specific stages of pancreatic cancer will receive either FOLFIRINOX or gemcitabine/nab-paclitaxel, then switch to the other if needed, plus the drug losartan. The goal is to see if this approach leads to more successful surgeries and longer survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.